NCT00658749View on ClinicalTrials.gov

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions
Asthma
Interventions
DRUG

AIR645

AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

DRUG

Physiologic saline solution

Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

Trial Locations (1)

92130

Contract Research Organization (CRO) appointed by Altair Therapeutics--Altair's offices are in:, San Diego

Sponsors
All Listed Sponsors
lead

Altair Therapeutics, Inc.

INDUSTRY

NCT00658749 - A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma | Biotech Hunter | Biotech Hunter